Recursion Pharma News and Activities

Recursion Pharma is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Recursion Pharma is a company listed under the stock ticker RXRX (US).

Acquisition, funding and merger involving Recursion Pharma.

• Recursion Pharma and Exscientia have merged  (posted on November 27 2024)..

View the org chart displaying its 35 main executives

Most searched biographies at Recursion Pharma

• Najat Khan, Chief Executive Officer and President
• Zavain Dar, Board Member
• Chris Gibson, Chairman of the Board

Popular executive movements at Recursion Pharma

• Kristen Rushton, Chief Operating Officer, has left the company  (posted on March 25 2026).
• David Mauro, Chief Medical Officer, will leave the company on Apr. 6, 2026  (posted on March 25 2026).
• Vicki Goodman will join the company as Chief Medical Officer on Apr. 6, 2026  (posted on March 25 2026).

Click here to view some more movements at Recursion Pharma

Create your alert
to follow the executive moves at Recursion Pharma.

Recursion Pharma has 1,913 competitors including Sanofi (France), Moderna (United States (USA)) and Eli Lilly (United States (USA)).

Popular M&A news in Pharmaceuticals

• Eli Lilly has acquired Centessa Pharmaceuticals (posted on June 24 2026).
• Polpharma has acquired Biofarm (posted on June 24 2026).
• AbbVie has announced the acquisition of Apogee Therapeutics  (posted on June 23 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Tracey Franklin - Chief People and Digital Technology Officer at Moderna
• Richard Saynor - Chief Executive Officer at Sandoz

Learn more about the Pharmaceuticals industry

Press releases by Recursion Pharma

• Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | Recursion Pharmaceuticals, Inc.
• How a First-of-its-Kind “Microglia Map” from Recursion and Roche and Genentech Could Unlock New Treatments for Neurodegenerative Diseases
• MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy | Recursion Pharmaceuticals, Inc.
• Leveraging the Power of Patient Data in AI Drug Discovery
• Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas | Recursion Pharmaceuticals, Inc.
• Recursion and Google Cloud Announce Expansion of Partnership to Support Drug Discovery with Cloud and Exploration of Generative AI Technologies
• Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma | Recursion Pharmaceuticals, Inc.
• Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability | Recursion Pharmaceuticals, Inc.
• Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities | Recursion Pharmaceuticals, Inc.
• Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer | Recursion Pharmaceuticals, Inc.
• View more press releases Close

Social media about Recursion Pharma

• Recursion Pharma on Wikipedia, Google News & Yahoo Finance
• Recursion Pharma on LinkedIn, X (Twitter) & YouTube